FDA Approves VONJO — Sobi, Inc.

Sobi, Inc. received FDA approval for VONJO (pacritinib) to treat adult patients with Philadelphia-negative myelofibrosis who have intolerant or refractory to ruxolitinib, a development expected to leverage the new drug's distinct mechanism to address a significant unmet patient need in the market. This approval expands Sobi's portfolio in hematologic malignancies and provides the company with a commercially distinct product to compete in the myelofibrosis therapeutic landscape.